Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Claritin-D 12-Hour ER Tablet (SAG vs Heist)
NCT03517930Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of loratadine + pseudoephedrine in allergic rhinitis (AR) (2 arms), sponsored by Bayer. Primary endpoints: Area Under the Curve from time 0 to the last measurable concentration and Maximum Plasma Concentration. Started Apr 2018; status: completed.
02
Drugs
loratadine + pseudoephedrine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT03517930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517930.